Risdiplam is approved for children older than 2 months with spinal muscular atrophy (SMA); an expanded approval would include the youngest infants before they show symptoms.
PTC Therapeutics said Tuesday that the FDA has granted priority review of a supplemental new drug application (sNDA) for Evrysdi (risdiplam) to expand the indication to include presymptomatic infants younger than 2 months with genetically confirmed spinal muscular atrophy (SMA).
Risdiplam was first approved by the FDA in August 2020 for children 2 months and older; it is the first oral drug given at home for infants and children with SMA.
SMA is a rare disease with different subtypes, type 0 through type 4; risdiplam is designed to treat SMA by increasing and sustaining the production of the SMN protein, which is critical for building and maintaining motor development.
Infants with SMA may appear fine at birth but fail to meet milestones ,and without intervention, they live for about 2 years.
The sNDA submission was based on interim data from the RAINBOWFISH study (NCT03779334), an open-label, single-arm, multicenter study, investigating the efficacy, safety, pharmacokinetics, and pharmacodynamics of risdiplam in infants (n = 25) from birth to 6 weeks (at first dose) who are not yet presenting symptoms.
In the study, which is still recruiting, 80% of presymptomatic infants with SMA treated with risdiplam for at least 12 months achieved motor milestones such as sitting without support, rolling, crawling, standing unaided, and walking independently.
"The results demonstrating that almost all of the presymptomatic infants achieved motor milestones comparable to healthy infants is tremendous," Stuart W. Peltz, PhD, CEO of PTC Therapeutics, said in a statement. "The granting of the priority review for Evrysdi recognizes this and the significant need to treat babies with SMA as early as possible. We are proud that such a transformative treatment for patients living with SMA came from our splicing platform."
Risplidam was based on PTC's splicing platform; it is sold by Roche and in the United States by Genentech.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More